Eye-Health Startup RetinAI Raises CHF 2.3 Million to Globalize its AI-Ophthalmology
scroll south
The $8 billion market for diagnosing and monitoring eye diseases is just the tip of the iceberg for RetinAI, founder Carlos Ciller says. Today's pre-series A investment unlocks international growth now, and his startup's expertise in artificial intelligence for eye health promises early diagnosis of brain and heart conditions in the future.
What is RetinaAI's mission and main innovation?
We are leading the transition to patient-specific, precision medicine for the most common eye and brain diseases. RetinAI is the first company offering software and tools for healthcare professionals to collect, organize and analyse health-data from patients' eyes.
What perspectives will this investment by btov partners and investiere open for the company?
What perspectives will this investment by btov partners and investiere open for the company?
It'll bring RetinAI closer to market leadership in AI in ophthalmology, a multi-billion market, and accelerate our expansion. We're going to hire the staff and gain the certifications neccessary to grow internationally. The $8 billion market for diagnosing and monitoring eye diseases is just the tip of the iceberg. Beyond that, our software's unique technical and clinical expertise could bring RetinAI into the early detection of degenerative brain conditions such as Alzheimer's, and monitoring the risk of heart attacks.
How do you see your next steps to your development?
The past months have been thrilling! We signed contracts with several pharmaceutical and medical device companies, resulting in the first recurring revenues for RetinAI. We're en-route for European certification of our first clinical product, a software as a medical device. We're going to bring more products to the market in the near future, and move in the U.S. and Asia.
You won Venture Kick in 2017 and seats on the Venture Leaders roadshows to Boston and China in the following years. RetinAI also ranked at the TOP 100 Swiss Startup Award last year. How did these programs help you to get to where you are today?
Every single of these programs brought us one step closer to success. Venture Kick, Venture Leaders, and the TOP 100 rankings are all seals of quality. The programs helped jumpstart our deep-tech startup, and supported us during a critical phase from our academic roots to becoming entrepreneurs.
Venturelab programs are and will be paramount for the success of Swiss startups, there’s absolutely no doubt in that!
How do you see your next steps to your development?
The past months have been thrilling! We signed contracts with several pharmaceutical and medical device companies, resulting in the first recurring revenues for RetinAI. We're en-route for European certification of our first clinical product, a software as a medical device. We're going to bring more products to the market in the near future, and move in the U.S. and Asia.
You won Venture Kick in 2017 and seats on the Venture Leaders roadshows to Boston and China in the following years. RetinAI also ranked at the TOP 100 Swiss Startup Award last year. How did these programs help you to get to where you are today?
Every single of these programs brought us one step closer to success. Venture Kick, Venture Leaders, and the TOP 100 rankings are all seals of quality. The programs helped jumpstart our deep-tech startup, and supported us during a critical phase from our academic roots to becoming entrepreneurs.
Venturelab programs are and will be paramount for the success of Swiss startups, there’s absolutely no doubt in that!
.jpg)
